Investor Toolkit on Human Rights

Proxy voting is an essential part of investors’ fiduciary duty and stewardship. The proxy voting data of the largest asset managers offers useful insights into how they exercise their oversight of managements’ decision-making, reveals how they align their recognition of material risk with their asset owner clients and how they address significant environmental, social and […]

The ability of asset owners to meet their long-term financial goals is severely challenged by risks such as climate change, persistent income inequality, and the inequitable delivery of healthcare that threaten our planet and its people. Because they impact all economic participants and demonstrate the interdependence of all players, these risks are considered systemic. They […]

This new report outlines the widespread human rights abuses in seafood supply chains across major U.S. supermarkets. This is a critical issue for investors. The report details the significant risks that human rights violations pose to supermarkets in investors portfolios. The report provides:  Access the full report to understand how to address these critical supply […]

ICCR Climate Crisis Issue Brief One, June 2024 The transition to carbon-neutral economies will require a vast quantity of minerals. In essence, we must shift from a fossil fuel-intensive economy to one based on minerals, which are needed to harness and store the energy in natural systems. Due to their importance in new technologies, economic […]

This guidance is a resource for investors to use when discussing responsible purchasing and contracting issues with companies.

The need to reduce GHG emissions to limit warming and reach net zero by 2050 or sooner has never been more urgent yet climate progress has been hindered for decades by aggressive lobbying on the part of corporations (mainly in the oil & gas sector) and their trade associations. Because investors understand that corporate climate […]

A new report published by the Access to Medicine Foundation. It is becoming increasingly clear that releasing antibiotic waste into the environment can drive antimicrobial resistance (AMR). In helping to curb this rapidly rising global health threat, pharmaceutical companies can ensure the production of their lifesaving antibiotics does not inadvertently contribute to drug resistance. A new […]

When pharmaceutical companies set targets for executive performance, and base the amount of their compensation on meeting those targets, they often use profit metrics that are not based on Generally-Accepted Accounting Principles (like “Adjusted Earnings Per Share”) which routinely filter out legal settlement costs and fines from the end result. By excluding the $5 billion […]

As long-term institutional investors we recognize that the global shift to net-zero requires an unprecedented economic transformation that will impact industries, jobs, and communities. We call on companies, investors, and policymakers to ensure this is a just transition that supports a racially and economically equitable, decarbonized economy by prioritizing “high-road” jobs, respect for human rights, […]